Intercept Pharma (ICPT) Posts Smaller-than-Expected Q2 Loss as Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
July 31, 2017 7:05 AM EDTWorldwide net Ocaliva® (obeticholic acid or OCA) 2Q 2017 sales of $30.4 millionAESOP Phase 2 trial in patients with PSC met its primary endpointCONTROL trial met its objective, confirming statin co-administration with OCA reduces LDL to below baseline levels in patients with NASH
Conference call scheduled for 8:30 a.m. ET today
NEW YORK, July 31, 2017 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel... More
